Another failed trial for Orphazyme’s ‘pipeline-in-a-product’ leaves shadow on drug’s future

The tumultuous ride for Orphazyme continued on Friday as the company announced that a pivotal trial for its lead drug arimoclomol failed yet again, this time in the treatment of ALS, seeding doubt in a drug that had recently been cleared by the FDA for priority review. The latest failure...

Click to view original post